Abaloparatide
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Abaloparatide is a synthetic 34-amino-acid peptide modeled on parathyroid hormone-related protein (PTHrP). It belongs to the anabolic, or bone-building, class of osteoporosis drugs, which work by stimulating new bone formation rather than simply slowing bone loss.
It was approved by the FDA in 2017 under the brand name Tymlos for postmenopausal women with osteoporosis at high risk for fracture, and its label was later expanded to include men with osteoporosis at high risk for fracture. Unlike many research peptides, abaloparatide has been studied in large randomized human trials.
In the phase 3 ACTIVE trial, once-daily abaloparatide was associated with substantial reductions in new vertebral and nonvertebral fractures compared with placebo over 18 months. It is frequently discussed alongside teriparatide, the earlier anabolic agent it is often compared to.
How it works
Abaloparatide acts as a selective agonist at the PTH1 receptor (PTH1R) on osteoblasts, the cells responsible for building bone. Activating this receptor triggers the cAMP signaling pathway and shifts bone remodeling toward net formation. It is commonly reported to bind preferentially to one receptor conformation (the RG state), which is thought to produce a transient anabolic signal.
This selectivity is the leading explanation offered for why abaloparatide has been observed to carry a lower risk of hypercalcemia than teriparatide in comparative studies, though the two agents share a broadly similar mechanism. The full clinical significance of these binding differences is still being characterized.
Reported benefits
- Increased bone mineral density at the spine and hip (human trial data)
- Reduced risk of new vertebral and nonvertebral fractures (studied in postmenopausal women)
- Anabolic (bone-forming) action, distinct from antiresorptive therapies
- Lower observed rate of hypercalcemia relative to teriparatide
These are outcomes reported in clinical studies of the approved product, not guaranteed individual results.
Considerations & side effects
Commonly reported side effects include dizziness, nausea, headache, palpitations, injection-site reactions, and elevated calcium in blood or urine. Orthostatic (positional) drops in blood pressure have been reported, particularly after the first few doses.
Regulatory labeling notes a boxed warning regarding a potential risk of osteosarcoma observed in rat studies, and cumulative lifetime use of abaloparatide together with other PTH-analog therapies is generally limited to two years. Because it is an approved prescription medicine, its use, dosing, and monitoring should be directed by a qualified clinician; the information here is educational and not a substitute for medical advice.
Frequently asked
What is abaloparatide?
A synthetic analog of parathyroid hormone-related protein (PTHrP) that acts as an osteoanabolic — bone-building — agent by selectively activating the PTH1 receptor on bone-forming cells.
Is abaloparatide FDA-approved?
Yes. It was approved by the FDA in 2017 (marketed as Tymlos) to treat postmenopausal women with osteoporosis at high risk for fracture, and later for men with osteoporosis at high risk for fracture.
How is abaloparatide different from teriparatide?
Both are anabolic PTH-receptor agonists, but abaloparatide preferentially binds a specific conformation of the PTH1 receptor, which is commonly reported to favor bone formation while carrying a lower observed risk of hypercalcemia than teriparatide.
What is it used for?
It is prescribed to increase bone density and reduce fracture risk in adults with osteoporosis who are at high risk of fracture or who have not tolerated other therapies.
References
Related compounds
FDA-approved anabolic bone-building agent comprising the first 34 amino acids of parathyroid hormone. Actively stimulates new bone formation for osteoporosis treatment.
An 11-amino-acid peptide modeled on the tissue-protective domain of erythropoietin that selectively activates the innate repair receptor, driving tissue protection and anti-inflammatory effects without raising red blood cell count. Studied for small-fiber and diabetic neuropathy.
Body Protection Compound-157. A pentadecapeptide derived from human gastric juice. Known for tissue healing, gut health, and injury recovery.